WHIPPANY, N.J., May 21, 2026
Bayer has announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for a supplemental New Drug Application (sNDA) for Kerendia® (finerenone) for the treatment of chronic kidney disease (CKD) associated with type 1 diabetes (T1D). The regulatory milestone marks a major advancement in the treatment landscape for patients with diabetic kidney disease and further strengthens Bayer’s growing presence in cardiovascular and renal medicine. If approved, finerenone could become one of the first targeted therapies specifically indicated for CKD linked to type 1 diabetes, addressing a significant unmet medical need affecting thousands of patients globally.
The FDA’s Priority Review designation shortens the regulatory review timeline and is typically granted to therapies that may offer substantial improvements in treatment effectiveness, safety, or patient care for serious medical conditions. Bayer stated that the submission is supported by data from the company’s Phase 3 FINE-ONE trial, which evaluated the efficacy and safety of finerenone in patients living with CKD associated with T1D.
Finerenone Expands Kidney Disease Treatment Potential
Kerendia® (finerenone) is a non-steroidal selective mineralocorticoid receptor antagonist (MRA) designed to reduce inflammation and fibrosis associated with chronic kidney and cardiovascular diseases. The therapy is already approved in multiple countries for the treatment of CKD associated with type 2 diabetes, where it has demonstrated the ability to reduce kidney disease progression and cardiovascular complications.
According to Bayer, the Priority Review application aims to expand finerenone’s indication into the type 1 diabetes population, where patients remain at particularly high risk for kidney failure, cardiovascular events, and long-term disease complications. Chronic kidney disease continues to represent one of the most serious and costly complications of diabetes worldwide, contributing significantly to mortality, hospitalization, dialysis dependency, and reduced quality of life.
Advertisement
The Phase 3 FINE-ONE study evaluated the safety and efficacy of finerenone in adults with CKD and type 1 diabetes, building on previous evidence demonstrating the anti-inflammatory and anti-fibrotic effects of mineralocorticoid receptor blockade. Bayer emphasized that there are currently limited approved therapies specifically targeting kidney disease progression in patients with type 1 diabetes, highlighting the potential importance of finerenone within nephrology and endocrinology treatment strategies.
FDA Priority Review Highlights Unmet Medical Need
The FDA’s decision to grant Priority Review underscores the urgent need for innovative treatment options capable of slowing kidney disease progression in patients with diabetes-related renal complications. Industry analysts continue to identify chronic kidney disease as one of the fastest-growing global healthcare burdens, particularly as diabetes prevalence continues increasing worldwide.
Patients with CKD associated with type 1 diabetes often face progressive renal decline that can eventually lead to end-stage kidney disease requiring dialysis or transplantation. In addition to renal complications, these patients also experience elevated risks of cardiovascular disease, heart failure, and premature mortality. Experts believe that earlier intervention using targeted anti-inflammatory therapies may significantly improve long-term outcomes and reduce healthcare system burden.
Bayer stated that finerenone’s mechanism of action may provide important clinical benefits by targeting pathways involved in fibrosis and inflammation, which are key contributors to kidney damage and cardiovascular disease progression. The company continues to strengthen its broader cardiorenal portfolio through ongoing clinical research and expanded regulatory filings across multiple therapeutic indications.
Cardiorenal Innovation Continues Accelerating
The FDA Priority Review further reinforces the growing importance of cardiorenal medicine, precision nephrology, and targeted anti-inflammatory therapies within the global pharmaceutical industry. Pharmaceutical companies are increasingly investing in kidney disease research due to rising disease prevalence, aging populations, and strong demand for therapies capable of delaying dialysis and improving patient survival.
Bayer remains one of the leading companies advancing innovation in cardiovascular and renal medicine, with finerenone positioned as a central component of its long-term strategy in chronic disease management. The latest regulatory milestone also reflects broader industry momentum toward developing therapies that simultaneously address kidney function, cardiovascular protection, and metabolic disease progression.
As regulatory review advances, healthcare professionals and patients alike continue closely monitoring the potential expansion of finerenone into type 1 diabetes-related kidney disease, an area where treatment options remain limited despite growing global clinical need.
Source: Bayer press release
